Search research articles
Contact Us
Filters
Showing results (91-100 of 123) with videos related to
Page
of 13
Sort By:
European Journal of Haematology
|
January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations
Alessandro Corso, Monia Marchetti, Monica Galli, et al.
Hematological Oncology
|
October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Blood
|
December 24, 2019
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study
Valerio De Stefano, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Advances
|
April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort
Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Leukemia
|
May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Tiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Haematologica
|
April 21, 2018
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
Antonio Cuneo, George Follows, Gian Matteo Rigolin, et al.
Cancers
|
January 11, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, et al.
Cancer
|
May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study
Francesca Palandri, Monia Marchetti, Elena M Elli, et al.
American Journal of Hematology
|
December 10, 2019
Second cancers in MPN: Survival analysis from an international study
Monia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Haematologica
|
January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study
Francesca R Mauro, Irene Della Starza, Monica Messina, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 123) with videos related to
Sort By:
Page
of 13
European Journal of Haematology
|
January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations
Alessandro Corso, Monia Marchetti, Monica Galli, et al.
Hematological Oncology
|
October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Blood
|
December 24, 2019
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study
Valerio De Stefano, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Advances
|
April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort
Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Leukemia
|
May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Tiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Haematologica
|
April 21, 2018
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
Antonio Cuneo, George Follows, Gian Matteo Rigolin, et al.
Cancers
|
January 11, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, et al.
Cancer
|
May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study
Francesca Palandri, Monia Marchetti, Elena M Elli, et al.
American Journal of Hematology
|
December 10, 2019
Second cancers in MPN: Survival analysis from an international study
Monia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Haematologica
|
January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study
Francesca R Mauro, Irene Della Starza, Monica Messina, et al.
Page
of 13